---
document_datetime: 2025-11-10 16:12:00
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/verquvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: verquvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3975247
conversion_datetime: 2025-12-26 20:29:55.805906
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Verquvo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Informatio n affected 3   | Summary                                                               |
|---------------------------------------|---------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|-----------------------------------|-----------------------------------------------------------------------|
| Variation type II / EMA/VR/0000257213 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL | 18/09/2025                          | 24/10/2025                                  | SmPC and PL                       | Please refer to Scientific Discussion Procedure No. EMA/VR/0000257213 |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | PRODUCTS - C.I.z Other variation - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application consisting of: Type II (C.I.4): Update of section 4.2 of the SmPC to update posology recommendations based on results from study VELOCITY as well as additional post-hoc analyses from VICTORIA. VELOCITY is a phase 2b open-label clinical study to evaluate the tolerability and safety of an initiation dose of 5 mg of Vericiguat in participants with chronic heart failure with reduced ejection fraction. The Package Leaflet is updated accordingly. Type IB (C.I.z): to propose minor corrections in Module 2.7.4 and   |            |     |             |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000284955 | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re-test period/storage period supported by real time data - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 29/07/2025 | N/A |             |
| PSUR / EMA/PSUR/0000269002            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     | maintenance |